MSI Methylation Sciences, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Burnaby BC Canada (2007)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2013
NCT04623034
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Alternative names

MSI Methylation Sciences, Inc.